VERV•benzinga•
Verve Therapeutics Ended Q3 2024 With Cash, Cash Equivalents, And Marketable Securities Of $539.9M With Cash Runway Through 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 5, 2024 by benzinga